Short Interest in GSK PLC Sponsored ADR (NYSE:GSK) Increases By 32.8%

GSK PLC Sponsored ADR (NYSE:GSK) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 14,906,130 shares, an increase of 32.8% from the December 15th total of 11,227,595 shares. Based on an average daily trading volume, of 2,617,064 shares, the short-interest ratio is currently 5.7 days. Approximately 0.8% of the shares of the company are short sold. Approximately 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 2,617,064 shares, the short-interest ratio is currently 5.7 days.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk purchased 1,470,000 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the acquisition, the insider directly owned 18,245,691 shares in the company, valued at approximately $346,668,129. The trade was a 8.76% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On GSK

Large investors have recently made changes to their positions in the stock. Bank & Trust Co boosted its stake in shares of GSK by 657.7% in the fourth quarter. Bank & Trust Co now owns 2,061 shares of the pharmaceutical company’s stock worth $101,000 after buying an additional 1,789 shares during the last quarter. First Bank & Trust raised its position in GSK by 10.1% during the fourth quarter. First Bank & Trust now owns 56,333 shares of the pharmaceutical company’s stock worth $2,763,000 after acquiring an additional 5,182 shares during the period. Peoples Bank KS increased its stake in GSK by 6.3% during the 4th quarter. Peoples Bank KS now owns 5,030 shares of the pharmaceutical company’s stock worth $247,000 after buying an additional 300 shares in the last quarter. Old Port Advisors raised its stake in GSK by 1.2% in the 4th quarter. Old Port Advisors now owns 68,327 shares of the pharmaceutical company’s stock valued at $3,351,000 after purchasing an additional 812 shares during the last quarter. Finally, Ransom Advisory Ltd raised its position in shares of GSK by 14.9% in the fourth quarter. Ransom Advisory Ltd now owns 4,475 shares of the pharmaceutical company’s stock valued at $219,000 after buying an additional 582 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a research note on Friday. Barclays lowered shares of GSK from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 6th. Jefferies Financial Group restated a “buy” rating on shares of GSK in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of GSK in a report on Monday, December 29th. Finally, Bank of America raised GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $44.13.

GSK Price Performance

NYSE GSK traded down $0.86 during trading hours on Monday, reaching $48.26. The company’s stock had a trading volume of 7,543,432 shares, compared to its average volume of 3,052,416. GSK has a 1 year low of $32.38 and a 1 year high of $51.46. The firm’s 50-day moving average price is $48.58 and its 200-day moving average price is $43.52. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95. The company has a market capitalization of $98.37 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 1.21 and a beta of 0.45.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to analyst estimates of $8.21 billion. GSK had a return on equity of 48.64% and a net margin of 17.16%.The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. On average, equities research analysts predict that GSK will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 8th. Investors of record on Friday, November 14th were paid a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, November 14th. GSK’s payout ratio is 48.02%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.